Septerna Inc's Business Segments

The company operates in the pharmaceutical and biotechnology sector, focusing on research and development of product candidates targeting metabolic-related diseases such as obesity and type 2 diabetes. Its principal programs, SEP-479 and SEP-631, are in various stages of preclinical and clinical trials. The company employs its proprietary Native Complex Platform® technology to develop oral small molecule therapies targeting G protein-coupled receptors, including GLP-1, GIP, and glucagon receptors. It holds intellectual property rights, including U.S. federal trademark filings and proprietary trademarks related to its name and logo. The company collaborates with partners such as Novo Nordisk A/S to support development and commercialization efforts, which may involve milestone and royalty payments. Its operations include conducting research, managing regulatory filings and approvals such as IND applications and FDA approvals, manufacturing product candidates through third-party manufacturers, and commercializing approved therapies. The company actively manages its intellectual property portfolio and seeks additional licensing and collaboration agreements. It communicates material information via its website and social media channels and adheres to disclosure obligations. The company faces risks related to clinical trial outcomes, regulatory approvals, intellectual property rights, competition, funding, and market conditions.

The company operates in a single reportable segment, as identified by its chief executive officer, who serves as the chief operating decision maker (CODM). This segment is defined based on the availability of separate financial information and is regularly reviewed by the CODM for resource allocation and performance evaluation.